Among the rich screen results, several intriguing genes (BATF, PRDM1, and TOX) and signalling cascades (JAK-STAT and NF-κB pathways) have been identified to extensively engage in multiple branches of T cell anti-tumour responses and might be leveraged to advance cancer immunotherapies (Fig. 6). This evidence concerns the gene PRDM1 and cancer.